Dna methylation-related marker for diagnosing tumor, and application thereof
AssigneeShanghai Public Health Clinical Center
InventorsWenqiang YU, Shihua DONG
Life of this patent
Estimating the term…
Abstract
Provided are DNA methylation related markers for diagnosis of tumors and application thereof. Disclosed are gene sequence regions having abnormal DNA methylation in the genome, named tumor markers CTSM-4F, CTSM-2BE, CTSM-3C, CTSM-4I. The methylation levels of those sequence regions are significantly different between tumor tissues and non-tumor tissues, with their CpG(s) hypermethylated in tumor tissues.
Claims18
1-13. (canceled)
An isolated polynucleotide, wherein, the polynucleotide is converted from the polynucleotide of SEQ ID NO:
- 1, 3, 5 or 7 or the fragments thereof, and as compared with the sequence of SEQ ID NO:
- 1, 3, 5 or 7, its cytosine C of the CpG site(s) with modification is unchanged, and the unmodified cytosine is converted into T.
A method for detecting tumor, comprises detecting the DNA methylation status of the polynucleotide with the nucleotide sequence shown in SEQ ID NO:
- 1, 2, 5 or 7 or the fragments thereof, if the CpG sites are significantly hypermethylated, the subject is high-risk for tumor.
A method of detecting the methylation profile of the polynucleotide of SEQ ID NO:
- 1, 3, 5 or 7 or the fragments thereof, or the polynucleotide of claim 1, a fragment thereof in a sample in vitro, comprising:
- (i) providing the sample and extracting DNA;
- (ii) treating the sample to be detected to convert the unmodified cytosine into uracil;
- the modification includes 5-methylation, 5-hydroxymethylation, 5-formylcytosine (5fC) or 5-carboxylcytosine (5-caC);
- (iii) analyzing the modification of the polynucleotide or a fragment thereof in the genomic DNA treated by step (ii).
Dependencies are inferred from the claim text.